Perampanel: A new agent for adjunctive treatment of partial seizures

American Journal of Health-System Pharmacy

Volumn 71, Issue 3, 2014, Pages 191-198

  Faulkner, Michele A ^a,b  

^a Sch of Pharm and Hlth Professions   (United States)

^b CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPA RECEPTOR; ANTICONVULSIVE AGENT; CARBAMAZEPINE; LEVONORGESTREL; MIDAZOLAM; OXCARBAZEPINE; PERAMPANEL; PHENYTOIN; PLACEBO; RIFAMPICIN; VALPROIC ACID; PYRIDONE DERIVATIVE;

AGGRESSION; ATAXIA; CONVULSION; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERANCE; DRUG WITHDRAWAL; EPILEPTIC STATE; FATIGUE; FOCAL EPILEPSY; GAIT DISORDER; HALF LIFE TIME; HEADACHE; HEART ARREST; HEMODIALYSIS PATIENT; HUMAN; IRRITABILITY; KIDNEY FUNCTION; LIVER DISEASE; MAXIMUM PLASMA CONCENTRATION; REVIEW; SCHIZOPHRENIA; SOMNOLENCE; TONIC CLONIC SEIZURE; ANIMAL; BIOAVAILABILITY; DRUG ANTAGONISM; DRUG INTERACTION; DRUG LABELING; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY;

ADMINISTRATION, ORAL; ANIMALS; ANTICONVULSANTS; BIOLOGICAL AVAILABILITY; DRUG INTERACTIONS; DRUG LABELING; EPILEPSIES, PARTIAL; HALF-LIFE; HUMANS; PYRIDONES; RECEPTORS, AMPA;

EID: 84904600381     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp130203     Document Type: Review

References (31)

1. Neligan A, Hauser WA, Sander JW. The epidemiology of the epilepsies. Handb Clin Neurol. 2012; 107:113-33.
2. Kwan P, Schachter SC, Brodie MJ. Current concepts: drug-resistant epilepsy. N Engl J Med. 2011; 365:919-26.
3. Kwan P, Sander JW. The natural history of epilepsy: an epidemiological view. J Neurol Neurosurg Psychiatry. 2004; 75:1376-81.
4. Potschka H. Pharmacological treatment strategies: mechanisms of antiepileptic drugs. Epileptology. 2013; 1:31-7.
5. Glutamate receptors. In: White HS, Rho JM, eds. Mechanisms of action of antiepileptic drugs. 1st ed. New York: Professional Communications; 2010:71-84.
6. Rektor I, Krauss GL, Bar M et al. Perampanel study 207: long-term open-label evaluation in patients with epilepsy. Acta Neurol Scand. 2012; 126:263-9.
7. Takagaki G. The dawn of excitatory amino acid research in Japan. The pioneering work by Professor Takashi Hayashi. Neurochem Int. 1996; 29:225-9.
8. During MJ, Spencer DD. Extracellular hippocampal glutamate and spontaneous seizure in the conscious human brain. Lancet. 1993; 341:1607-10.
9. Le DA, Lipton SA. Potential and current use of N-methyl-D-aspartate (NMDA) receptor antagonists in diseases of aging. Drugs Aging. 2001; 18:717-24.
10. Rogawski MA. Revisiting AMPA receptors as an antiepileptic drug target. Epilepsy Curr. 2011; 11:56-63.
11. Plosker GL. Perampanel as adjunctive therapy in patients with partial onset seizures. CNS Drugs. 2012; 26:1085-96.
12. Meldrum BS, Rogawski MA. Molecular targets for antiepileptic drug development. Neurotherapeutics. 2007; 4:18-61.
13. Mayer ML. Glutamate receptor ion channels. Curr Opin Neurobiol. 2005; 15: 282-8.
14. Rosenmund C, Stern-Bach Y, Stevens CF. The tetrameric structure of a glutamate receptor channel. Science. 1998; 280:1596-9.
15. Meldrum BS. Implications for neuroprotective treatments. Prog Brain Res. 2002; 135:487-95.
16. 2+ and desensitization. Neurochem Res. 2003; 28:1495-9.
17. Löscher W, Schmidt D. Perampanel - new promise for refractory epilepsy? Nat Rev Neurol. 2012; 8:661-2. News.
18. Franco V, Crema F, Iudice A et al. Novel treatment options for epilepsy: focus on perampanel. Pharmacol Res. 2013; 70:35-40.
19. Hussein Z, Ferry J, Krauss G et al. Demographic factors and concomitant antiepileptic drugs have no effect on the pharmacodynamics of perampanel. Presented at 64th Annual Meeting of the American Academy of Neurology. New Orleans, LA; 2012 Apr 26.
20. Hussein Z, Critchley D, Ferry J et al. Population pharmacokinetics of perampanel, a selective, noncompetitive AMPA receptor antagonist, in patients with refractory partial-onset seizures participating in a randomized, double-blind, placebo-controlled phase III study. Epilepsia. 2011; 52(suppl 6):248-9. Abstract.
21. Fuseau E, Templeton D, Hussein Z. Population pharmacokinetics and pharmacodynamics of perampanel in patients with refractory partial seizures. Epilepsy Curr. 2011; 11(suppl 1):1.254. Abstract.
22. Templeton D. Pharmacokinetics of perampanel, a highly selective AMPA-type glutamate receptor antagonist. Epilepsia. 2009; 50(suppl 11):98. Abstract.
23. Laurenza A, Ferry J, Hussein Z. Population pharmacokinetics and pharmacodynamics of perampanel: a pooled analysis from three phase III trials. Epilepsy Curr. 2012; 12(suppl 1):2.231. Abstract.
24. Fycompa (perampanel) package insert. Woodcliff Lake, NJ: Esai; 2012 Oct.
25. French JA, Krauss GL, Biton V et al. Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304. Neurology. 2012; 79: 589-96.
26. French JA, Krauss GL, Steinhoff BJ et al. Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305. Epilepsia. 2013; 54:117-25.
27. Krauss GL, Serratosa JM, Villanueva V. Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 306. Neurology. 2012; 78:1408-15.
28. Krauss GL, Perucca E, Ben-Menachem E et al. Perampanel, a selective, noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partial-onset seizures: interim results from phase III, extension study 307. Epilepsia. 2013; 54:126-34.
29. Trinka E, Straub H, Squillacote D et al. Analysis of seizure frequency reduction by concomitant antiepileptic drug (AED) use with adjunctive perampanel: pooled phase III results. Epilepsia. 2012; 53(suppl 5):194-5. Abstract.
30. Krauss GL, Bar M, Biton V et al. Tolerability and safety of perampanel: two randomized dose-escalation studies. Acta Neurol Scand. 2012; 125:8-15.
31. Gilbert JA. Eisai files a writ of mandamus as a last resort to get DEA to schedule Fycompa. www.fdalawblog.net/fda-law-blog-hyman-phelps/2013/08/eisai-files-a-writ-of-mandamus-as-a-last-resort-to-get-dea-to-schedule-fycompa-.html (accessed 2013 Nov 1).